PD-1 and PD-L1 Inhibitors Market - Global Growth, Trends and Forecast (2022 - 2027) By Types, By Application, By Regions and By Key Players: Merck & Co., Inc. (NYSE :MRK), Bristol-Myers Squibb Company (NYSE :BMY)

Registering a CAGR of 18.5% over the forecast period, the market value of PD-1 and PD-L1 Inhibitors is expected to reach US$ 1, 13,500.64 million in the year 2027.

PD-1 and PD-L1 Inhibitors Market Overview

PD-1 inhibitors and PD-L1 inhibitors are two types of checkpoint inhibitor anticancer drugs that block the activity of PD-1 and PDL1 resistance checkpoint proteins on the cell surface. Immune checkpoint inhibitors are becoming a popular therapy option for a variety of cancers.

Due to a rise in cancer frequency across geographies and increased knowledge of immune checkpoint inhibitors, the global market for PD-1 and PD-L1 inhibitors is growing. Furthermore, the market is expected to grow as a result of technical developments in cancer screening techniques, growing healthcare costs, increased government activities to combat cancer, and higher public awareness. The International Agency for Research on Cancer (IARC) published an updated Globocan 2020 study on the 14th of December, stating that the global cancer burden has climbed to 19.3 million cases and 10 million cancer deaths in 2020.

The report aspects discussed the profile of the top manufacturers of the global PD-1 and PD-L1 Inhibitors market. These aspects include financial status of major companies, trending advancements and entire market scenario. Growth of the report have examined PD-1 and PD-L1 Inhibitors Market production, demand and growth potential, geographic analysis, as well as current market developments in various regions and countries.

Industry News and Updates:

Innovent and Laekna Therapeutics Enter a Partnership Agreement to Co-Develop Combination Therapy of Sintilimab and Afuresertib in Clinical Studies in China

Jul 6th, 2021: Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, and Laekna Therapeutics Shanghai Co., Ltd. (Laekna), an emerging innovative pharma company based in China’s “Zhangjiang Pharma Valley” and New Jersey in the U.S., focusing on developing new ground-breaking innovative therapies to treat cancer and liver diseases, today jointly announced they have entered into a collaboration agreement to evaluate the combination of Innovent’s PD-1 inhibitor sintilimab and Laekna’s pan-AKT kinase inhibitor afuresertib. 

Bristol Myers Squibb Announces Opdivo (nivolumab) plus Chemotherapy and Opdivo plus Yervoy (ipilimumab) Demonstrate Superior Survival Benefit Compared to Chemotherapy in Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma

April 8, 2021: Bristol Myers Squibb (NYSE: BMY) today announced positive topline results from the Phase 3 CheckMate -648 trial evaluating treatment with Opdivo (nivolumab)plus chemotherapy or Opdivo plus Yervoy (ipilimumab) in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC).

What are the major Applications, Types and Regions for PD-1 and PD-L1 Inhibitors Market?

Market is segmented based on the type, applications, companies and regions.

By Type, it is segmented into

• PD-1 Inhibitors


• PD-L1 Inhibitors


• Others

By Application, it is segmented into

• Solid Tumors


• Blood-related Tumors


• Others

PD-1 and PD-L1 Inhibitors Market Regional Analysis

North America is expected to dominate the overall PD-1 and PD-L1 inhibitors market throughout the forecast period. The dominance is due to the growing prevalence of various chronic diseases like diabetes, skin cancer, urothelial carcinomas, lung cancers, and the presence of a huge population of baby boomers during the forecast period in the United States necessitated the efficient treatment. For instance, according to the American Cancer Society Inc. estimates for 2020, lung cancer is the second most common cancer leading to 135,720 deaths in both men and women. The statistics also report that about 13% of all lung cancers are small cell lung cancer (SCLC) and 84% non-small cell lung cancer (NSCLC) in the United States which is expected to continue in the future resulting in higher demand for these products fueling the market in the region. Moreover, the significant share of market revenue in the region can be attributed to the presence of major key players and huge investment in the R&D activities to develop new products and generic drugs along with incentives by the government to encourage the innovations to decrease the growing disease burden which is likely to provide more opportunities to the growth of PD-1 and PD-L1 inhibitors market during the forecast period.

• North America
  
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East & Africa
  
  
  • Latin America
  
  
  
  

The PD-1 and PD-L1 Inhibitors Market describes the factors driving the global growth opportunities in upcoming years and highlights market channels. In addition, the report analyzes market size and share, trends, by geographic region, end-use type and segment. It focuses extensively on revealing a detailed regional analysis. The Global PD-1 and PD-L1 Inhibitors Market report also conducted a PESTEL analysis of the industry to study the main influencing factors and entry barriers of the industry.

What is our PD-1 and PD-L1 Inhibitors Market report scope?

Scope of the Report covers PD-1 and PD-L1 Inhibitors Market with detailed analysis of the overall scenario for the market. It also highlights the business participants environment in the global marketplace. This report also provides an overview of leading companies covering the latest successful marketing strategies, market contributions, current and historical background and latest market happenings to help key organizations to grow and generate larger profits. Business players will greatly benefit from this PD-1 and PD-L1 Inhibitors Market analysis report as it has vital details to provide about regional markets, expected opportunities for the prediction time period 2022-2027. Growth between segments is used to understand the different growth factors that are expected to dominate the market as a whole and to develop strategies to differentiate between key applications and target markets. It further reveals how worldwide market is working through efficient information graphics.

Key Takeaways from this PD-1 and PD-L1 Inhibitors Report

• Evaluate PD-1 and PD-L1 Inhibitors market potential through analyzing growth rates (CAGR %), Volume (Units) and Value ($M) data given at country level - for product types, end use applications and by different industry verticals.


• Understand the different dynamics influencing the market - growth driving factors, specific challenges and hidden opportunities.


• Get in-depth insights on your competitor performance – revenue, shares, business strategies, financial benchmarking, product benchmarking, SWOT analysis and more.


• Analyze the sales and distribution channels across geographies to enhance top-line revenues.


• Understand the demanding supply chain with a deep dive on the value augmentation at each, in order to optimize value and bring efficiencies in your processes.


• Get a quick outlook on the PD-1 and PD-L1 Inhibitors market entropy - M&A's, deals, partnerships, product launches of all key players for the past 5 years.


• Evaluate the import-export statistics, supply-demand and competitive landscape for more than top 20 countries globally for the market.

All our reports are custom made to your company needs to a certain extent, we do provide 5 free consulting hours along with purchase of each report, and this will allow you to request any additional data to customize the report as your needs.

Frequently Asked Questions

What is the study period of this market?

The PD-1 and PD-L1 Inhibitors Market is studied from 2017 - 2027.

Who are the key players in PD-1 and PD-L1 Inhibitors Market?

Merck & Co., Inc. (NYSE :MRK), Bristol-Myers Squibb Company (NYSE :BMY), Roche, AstraZeneca, Ono Pharmaceutical, Regeneron, Innovent, Hengrui Medicine, Junshi Biosciences, Merck KGaA and others..

What are the significant types of PD-1 and PD-L1 Inhibitors Market?

PD-1 Inhibitors, PD-L1 Inhibitors, Others.

What are the major end-use applications of the PD-1 and PD-L1 Inhibitors Market?

Solid Tumors, Blood-related Tumors, Others.

What segments are covered in the PD-1 and PD-L1 Inhibitors Market report?

The Global PD-1 and PD-L1 Inhibitors Market is Segmented on the basic of Product, Application, and Geography.

How can I get a sample report/company profile for the PD-1 and PD-L1 Inhibitors Market?

The sample report for the PD-1 and PD-L1 Inhibitors Market can be obtained on demand from the website. Also, the 24*7 chat support & direct call services are provided to procure the sample report